GURUFOCUS.COM » STOCK LIST » USA » NAS » Century Therapeutics Inc (NAS:IPSC) » Definitions » Beneish M-Score
Switch to:

Century Therapeutics (NAS:IPSC) Beneish M-Score

: 0.92 (As of Today)
View and export this data going back to 2021. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.92 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Century Therapeutics's Beneish M-Score or its related term are showing as below:

IPSC' s Beneish M-Score Range Over the Past 10 Years
Min: 0.92   Med: 1.05   Max: 1.18
Current: 0.92

During the past 4 years, the highest Beneish M-Score of Century Therapeutics was 1.18. The lowest was 0.92. And the median was 1.05.


Century Therapeutics Beneish M-Score Historical Data

The historical data trend for Century Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Beneish M-Score
- - - -

Century Therapeutics Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 1.18 0.92

Competitive Comparison

For the Biotechnology subindustry, Century Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Century Therapeutics Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Century Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's Beneish M-Score falls in comparison to its industry or sector. The grey bar indicates the Beneish M-Score's extreme value range as defined by GuruFocus.



Century Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Century Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 3.2299+0.528 * 1+0.404 * 3.4722+0.892 * 1.8598+0.115 * 0.5067
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6419+4.679 * -0.072462-0.327 * 1.266
=0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $1.71 Mil.
Revenue was 0.099 + 1.72 + 0.521 + 2.224 = $4.56 Mil.
Gross Profit was 0.099 + 1.72 + 0.521 + 2.224 = $4.56 Mil.
Total Current Assets was $161.28 Mil.
Total Assets was $417.16 Mil.
Property, Plant and Equipment(Net PPE) was $108.76 Mil.
Depreciation, Depletion and Amortization(DDA) was $11.75 Mil.
Selling, General, & Admin. Expense(SGA) was $33.44 Mil.
Total Current Liabilities was $19.16 Mil.
Long-Term Debt & Capital Lease Obligation was $40.83 Mil.
Net Income was -33.291 + -31.264 + -31.682 + -30.749 = $-126.99 Mil.
Non Operating Income was -4.406 + -0.194 + 2.069 + 1.387 = $-1.14 Mil.
Cash Flow from Operations was -19.25 + -29.219 + -22.907 + -24.238 = $-95.61 Mil.
Total Receivables was $0.28 Mil.
Revenue was 1.396 + 1.058 + 0 + 0 = $2.45 Mil.
Gross Profit was 1.396 + 1.058 + 0 + 0 = $2.45 Mil.
Total Current Assets was $383.79 Mil.
Total Assets was $532.58 Mil.
Property, Plant and Equipment(Net PPE) was $94.70 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.92 Mil.
Selling, General, & Admin. Expense(SGA) was $28.01 Mil.
Total Current Liabilities was $21.57 Mil.
Long-Term Debt & Capital Lease Obligation was $38.93 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.706 / 4.564) / (0.284 / 2.454)
=0.373795 / 0.115729
=3.2299

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.454 / 2.454) / (4.564 / 4.564)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (161.28 + 108.764) / 417.159) / (1 - (383.793 + 94.699) / 532.584)
=0.352659 / 0.101565
=3.4722

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4.564 / 2.454
=1.8598

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.923 / (4.923 + 94.699)) / (11.754 / (11.754 + 108.764))
=0.049417 / 0.097529
=0.5067

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(33.437 / 4.564) / (28.01 / 2.454)
=7.326249 / 11.414018
=0.6419

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((40.833 + 19.161) / 417.159) / ((38.934 + 21.569) / 532.584)
=0.143816 / 0.113603
=1.266

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-126.986 - -1.144 - -95.614) / 417.159
=-0.072462

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Century Therapeutics has a M-score of 0.92 signals that the company is likely to be a manipulator.


Century Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Century Therapeutics (NAS:IPSC) Business Description

Century Therapeutics logo
Traded in Other Exchanges
N/A
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
Executives
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Daphne Quimi director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Joseph Jimenez director ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Hyam Levitsky officer: President of R&D C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Adrienne Farid officer: Chief Operations Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Gregory Russotti officer: Chief Technology Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Osvaldo Flores officer: Chief Executive Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr officer: VP of Finance and Operations C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Michael Craig Diem officer: Chief Business Officer 3675 MARKET STREET, PHILADELPHIA PA 19104
Luis Borges officer: Chief Scientific Officer TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080